Prognostic Risk Evaluation for Hypereosinophilic Syndrome (HES) and Idiopathic Hypereosinophilia (IHE) and the Role of Next-generation Sequencing

Overview

About this study

The purpose of this study is to:

To identify predictors of inferior overall survival in HES/IHE patients including molecular parameters using next-generation sequencing performed at the point of clinical care
To apply the previously proposed prognostic model that included myeloid-relevant gene mutations to identify high-risk HES/IHE patients for closer monitoring

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Diagnosis of hypereosinophilic syndrome (HES) or idiopathic hypereosinophilia (IHE)

Exclusion Criteria:

None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Thanai Pongdee, M.D.	Open for enrollment	Contact information: Kay Bachman R.N., C.C.R.C. (507) 284-5689 bachman.kay@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thanai Pongdee, M.D.

Open for enrollment

Contact information:

Kay Bachman R.N., C.C.R.C.

(507) 284-5689

bachman.kay@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials